AxoGen announces full launch of Avive+ Soft Tissue Matrix

Axogen announces the launch of its newest product, Avive+ Soft Tissue Matrix . Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration FDA requirements for Human Cellular and Tissue-based Products or HCT/P, under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. “Product innovation is integral to our mission at Axogen,” stated Karen Zaderej, Chairman, CEO, and President. “With the introduction of Avive+ Soft Tissue Matrix, we are excited to enhance our comprehensive solutions for nerve protection and address a significant need for patients with compression or non-transected nerve injuries.”